Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|January 18, 2023

Dr. Rubenstein on how 2023 CPT changes will affect urology

Author(s)Urology Times staff

“Now, we only have 1 code set that we have to worry about instead of 2 code sets,” says Jonathan Rubenstein, MD.

In this video, Jonathan Rubenstein, MD, discusses recent changes in CPT hospital coding. Rubenstein is compliance officer and medical director of coding and reimbursement, United Urology Group and Chesapeake Urology, Towson, Maryland.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

When a Roth conversion makes sense—and when it doesn’t

ByJulie Khazan, CFP

December 2nd 2025

Detailed view of medical bill codes on a spreadsheet displayed on a computer. Office desk with modern technology and financial documents | Image Credit: © Thirawat - stock.adobe.com

Simplifying stent removal coding: Understanding 52310 vs 52315

ByJonathan Rubenstein, MD,Mark Painter

November 28th 2025

Urology health policy in 2025: Big wins, ongoing battles, and what comes next

ByMara R. Holton, MD

November 26th 2025

Jonathan Henderson, MD, outlines key lessons in urology practice management

ByJonathan Henderson, MD

November 11th 2025

Drs. Amy and Michelle Pearlman provide an overview of their practice, Prime Institute

ByAmy M. Pearlman, MD,Michelle Pearlman, MD

November 10th 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Experts urge FDA to revisit labeling for testosterone replacement therapy in men

Sildenafil cream for female sexual arousal disorder available to prescribe in select states

FDA approves first-line Zenflow system for the treatment of BPH

FDA approves gepotidacin for uncomplicated urogenital gonorrhea

Pearls & Perspectives: Reimagining Fertility & Sexual Health After Spinal Cord Injury, with Emad Ibrahim, MD, HCLD

© 2025 MJH Life Sciences^®

All rights reserved.